Within the myelodysplastic syndrome (MDS) work package of the European LeukemiaNet,
an Expert Panel was selected according to the framework elements of the National Institutes …

This is the sixth special report that the European Society for Blood and Marrow
Transplantation regularly publishes on the current practice and indications for …

PURPOSE Allogeneic hematopoietic cell transplantation (HCT) is the only potentially
curative therapy for myelodysplastic syndromes (MDS), although it is infrequently offered to …

Abstract The European Group for Blood and Marrow Transplantation regularly publishes
special reports on the current practice of haematopoietic SCT for haematological diseases …

Acute myeloid leukemia (AML) was initially subdivided according to morphology (the French-
American-British system), which proved helpful in pathologic categorization. Subsequently …

The development of new therapeutic strategies for myelodysplastic syndromes (MDS) has
gained new momentum fueled by improved characterization of the disease's natural history …

Background Allogeneic stem cell transplantation is usually considered the only curative
treatment option for patients with advanced or transformed myelodysplastic syndromes in …

Allogeneic hematopoietic stem cell transplantation (SCT) is well accepted as a curative
treatment approach for younger patients with myelodysplastic syndrome (MDS) and has …

Abstract Treatment algorithms for poor cytogenetic-risk myelodysplastic syndrome (MDS),
defined by chromosome 7 abnormalities or complex karyotype (CK), include allogeneic stem …

Clinical research examining the role of hematopoietic stem cell transplantation (SCT) in the
therapy of myelodysplastic syndromes (MDS) in adults is presented and critically evaluated …